Recent Updates
Recently added Catalysts
MIRA Positive Sentiment

MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies

Monday, March 23, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: MIRA Pharmaceuticals has reported promising preclinical data for Mira-55, indicating it does not cause CNS side effects linked to THC or Rimonabant. The compound has previously shown the ability to provide pain relief comparable to morphine without the associated risks of opioids. This data supports the company's upcoming IND submission for treating inflammatory pain.
Price reaction · baseline $0.92 (2026-03-20 close) · hit pre-market · clean, no other MIRA news in the window
day 0 close · peak
+22.3%
day 1
+14.1%
day 3
+15.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Mira-55 shows no CNS side effects associated with THC or Rimonabant.
  • Demonstrated morphine-comparable pain relief without opioid risks.
  • Supports planned IND submission for inflammatory pain.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+26%
120-day peak, hindsight
Typical move
2.7%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Ketamir-2
Phase 1 · Healthy Adult Participants

Full Press Release Details

Previously shown to deliver morphine-comparable pain relief without opioid-related risks in a validated inflammatory pain model, supporting planned IND submission for inflammatory pain MIAMI, FL / ACCESS Newswire / March 23, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company developing novel therapies for neurologic, neuropsychiatric, and metabolic disorders, today announced new preclinical data demonstrating that Mira-…
You can read the full content here

Frequently Asked Questions

What is Mira-55's significance in pain relief?

Mira-55 provides morphine-comparable pain relief without opioid-related risks.

What side effects are associated with Mira-55?

Mira-55 shows no CNS side effects linked to THC or Rimonabant.

What is the planned next step for MIRA Pharmaceuticals?

The company is preparing an IND submission for inflammatory pain.

ShareAdd on Google
Tags: MIRA Viatris Investor Conferences Healthcare MIRA Pharmaceuticals Mira-55 CNS side effects opioid risks inflammatory pain
Last updated: Mar 23, 2026

Biotech snapshot

Cash runway
$8M liquidity · $0M/mo burn
~19 mo
Low dilution risk
Lead asset
Ketamir-2Phase 1
Healthy Adult Participants →

Catalyst track record

+26%
best trade around MIRA's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for MIRA.

See every catalyst's timing & PoA →